(A) Binding assay of EV-A71_812 to L929-SCARB2 and PSGL1 overexpressing cells in either the presence or absence of MADAL385. A condition with cells pre-treated with sodium chlorate (NaClO3, 50mM) which prevents cell-surface sulfation was also included. The graph represents the RNA levels of bound virus relative to the L929-SCARB2 infected and L929-SCARB2 infected pre-treated with NaClO3 condition, respectively. (B) MADAL385 inhibits EV-A71 infection of L929-SCARB2 and PSGL1 cells. L929-SCARB2 and PSGL1 cells were infected with EV-A71_812 in presence or absence of MADAL385 and in presence or absence of NaClO3 (50mM). Twenty-four hours (24h) after infection, viral progeny was quantified by end-point titration. Error bars represent the mean ± ...
<p>(A, C) HGF cells were pre-treated with 10 µg/mL of LTA from <i>S. aureus</i> or LPS from <i>P. gi...
<p>Parental CHO cells (−−−−) and stably overexpressing CHO NPC1 cells (− − −) were pre-treated with ...
Uninfected HFFs, ARPE-19, and SHSY-5Y were treated with the indicated concentrations of Cl-A (A) and...
(A) Structural formula of MADAL385. (B) Concentration dependent inhibition of EV-A71 BrCr replicatio...
(A) Scheme of the receptor binding inhibition assay setup. (B) Relative neutralization of EV-A71 BrC...
(A) EV-A71 BrCr and resistant strains were used to infect RD cells in presence or absence of MADAL38...
<p><b>A)</b> Mean (N = 2) viral titers (±SEM) expressed as log TCID<sub>50</sub>/ml (median tissue c...
<p>Cells were infected with EV-A71 (moi 0.5), and various concentrations of LiCl were added to the i...
<p>Pretreatment of RD cells with 2 µM or 0 µM (0.1% DMSO) of GA for one hour before MOI = 0.01 of EV...
<p>RD cells were transfected individually with 200 pmoles of HSP90α, HSP90β, or the control siRNA, a...
<p>Chemical structures of compound HL051001P2 <b>(A)</b> and CsA <b>(B)</b>. After the RD cells were...
<p>(A) RD (left) or Jurkat (right) cells were infected with EV71-02363 mutants at 1 CCID<sub>50</sub...
(A) Structure of 3.3 (left) and inhibition of transduction by MLV pseudotyped with the indicated vir...
<p>U87MGs were pre-treated with DMSO or BAY-11-7082 (1 µM) for 2 hours. The conditioned media (media...
<p>(A) An EV-A71 pentamer shown with the 5-fold vertex at the center. VP1-98 (red) was mutated in an...
<p>(A, C) HGF cells were pre-treated with 10 µg/mL of LTA from <i>S. aureus</i> or LPS from <i>P. gi...
<p>Parental CHO cells (−−−−) and stably overexpressing CHO NPC1 cells (− − −) were pre-treated with ...
Uninfected HFFs, ARPE-19, and SHSY-5Y were treated with the indicated concentrations of Cl-A (A) and...
(A) Structural formula of MADAL385. (B) Concentration dependent inhibition of EV-A71 BrCr replicatio...
(A) Scheme of the receptor binding inhibition assay setup. (B) Relative neutralization of EV-A71 BrC...
(A) EV-A71 BrCr and resistant strains were used to infect RD cells in presence or absence of MADAL38...
<p><b>A)</b> Mean (N = 2) viral titers (±SEM) expressed as log TCID<sub>50</sub>/ml (median tissue c...
<p>Cells were infected with EV-A71 (moi 0.5), and various concentrations of LiCl were added to the i...
<p>Pretreatment of RD cells with 2 µM or 0 µM (0.1% DMSO) of GA for one hour before MOI = 0.01 of EV...
<p>RD cells were transfected individually with 200 pmoles of HSP90α, HSP90β, or the control siRNA, a...
<p>Chemical structures of compound HL051001P2 <b>(A)</b> and CsA <b>(B)</b>. After the RD cells were...
<p>(A) RD (left) or Jurkat (right) cells were infected with EV71-02363 mutants at 1 CCID<sub>50</sub...
(A) Structure of 3.3 (left) and inhibition of transduction by MLV pseudotyped with the indicated vir...
<p>U87MGs were pre-treated with DMSO or BAY-11-7082 (1 µM) for 2 hours. The conditioned media (media...
<p>(A) An EV-A71 pentamer shown with the 5-fold vertex at the center. VP1-98 (red) was mutated in an...
<p>(A, C) HGF cells were pre-treated with 10 µg/mL of LTA from <i>S. aureus</i> or LPS from <i>P. gi...
<p>Parental CHO cells (−−−−) and stably overexpressing CHO NPC1 cells (− − −) were pre-treated with ...
Uninfected HFFs, ARPE-19, and SHSY-5Y were treated with the indicated concentrations of Cl-A (A) and...